The program is run by the agency’s Office of Orphan Products Development. The guidance explains how manufacturers should define a patient population for the device, demonstrate the device’s efficacy for that group and how demonstrating efficacy varies whether the device treats or diagnoses a disease or condition.
Related Articles on the FDA:
Commentary: Free the FDA
FDA Approves Intuitive Surgical’s Single-Site Instrumentation for Gallbladder Surgery
FDA Finds Problems in Johnson & Johnson Contract Drug Factory
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.